Details of the Drug Combinations

General Information of This Drug (ID: DM5H2W9)

Drug Name

dioscin DM5H2W9

Synonyms

Dioscin; 19057-60-4; Collettiside III; Dioscine; CHEBI:74023; CCRIS 4123; UNII-3B95U4OLWV; 3-O-(Rhaalpha1-4(Rhaalpha1-2)Glcbeta)-(25R)-spirost-5-en-3beta-ol; 3-O-[alpha-L-Rha-(1->4)-[alpha-L-Rha-(1->2)]-beta-D-Glc]-diosgenin; 3-O-[alpha-L-Rhap-(1->4)-[alpha-L-Rhap-(1->2)]-beta-D-Glcp]-diosgenin; (25R)-spirost-5-en-3beta-yl alpha-L-rhamnopyranosyl-(1->2)-[alpha-L-mannopyranosyl-(1->4)]-beta-D-glucopyranoside; 3B95U4OLWV; AC1L3OGN; Dioscin(Collettiside III); Dioscin (Collettiside III); GTPL840

Indication

Disease Entry	ICD 11	Status	REF
Hepatic fibrosis	DB93.0	Preclinical	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dioscin + Ruxolitinib	DC2HNQ5	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[2]
Dioscin + Idarubicin	DCW18N3	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
------------------------------------------------------------------------------------

References

1	Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.